1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations.Distinctive Features:• Applications to this award mechanism must include a clinical trial.• Projects can range from phase 0 to phase III.• If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial.• Applications are required to include patient advocates.• Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.
Funding Opportunity Number: HT942526PRCRPCTA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $45M total program funding.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility. Confirm the full requirements in the official notice before applying.
The current listing shows $45M total program funding. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for DoW Peer Reviewed Cancer, Clinical Trial Award are due October 5, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Yes — DoW Peer Reviewed Cancer, Clinical Trial Award is offered by Defense Health Agency Contracting Activity - DHACA and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Open Competition: Implementation of Findings From PCORI's Research Investments PCORI Funding Announcement -- Cycle 3 2026 is sponsored by Patient-Centered Outcomes Research Institute (PCORI). This PFA seeks to fund implementation projects that promote the uptake of peer-reviewed findings from specific PCORI-funded patient-centered comparative clinical effectiveness research (CER) in the context of the body of related evidence.
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Mentored Clinical Research Award (MCRA) supports patient-oriented vision injury research conducted by highly motivated military or civilian clinicians in training. The MCRA may be used to support a standalone study of high impact to vision injury care or the generation of clinical research data in preparation for a more expansive study. Research must align with at least one of the FY26 VRP Focus Areas. The MCRA may not be used to support preclinical research or clinical trials. Distinctive Features: · Key personnel must include an established clinician or Ph.D. clinical scientist, who will serve as Principal Investigator (PI) and a clinician in training (e.g., a fellow, resident, junior clinician, clinician in a Ph.D. program), who will conduct the proposed research under mentorship of the PI, with support from supporting personnel as appropriate. · The clinician in training should have sufficient time remaining in their training program to complete the research proposed under the MCRA. · Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact and Personnel. · Programmatic review criteria include adherence to the intent of the MCRA, contribution to program portfolio, relative impact and relevance to military health. · Applicants must submit documentation of Institutional Review Board (IRB)/Ethics Committee (EC) approval or exemption by January 1, 2027, in order for the MCRA application to be considered for funding. https://cdmrp.health.mil/pubs/press/2026/vrppreann Funding Opportunity Number: HT942526VRPMCRA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $150K total program funding.
HRSA-27-006 and HRSA-27-007 post September 18, 2026 and both close October 19 — $711.4 million across 189 awards for service areas that already have a health center in them. The incumbent is defending. Everyone else is holding a free option.
Read articleCDMRP's FY26 portfolio funds 34 programs, and October 2026 is dense with full-application deadlines: PRCRP October 5, PCRP October 7, MRP October 14. Every one of them is gated behind a pre-application that closed months earlier. Here is what that two-step structure actually costs applicants, and how to be inside the gate for FY27.
Read articleUSDA has obligated roughly $1 billion in emergency funds against New World screwworm and awarded $105 million to 40 Grand Challenge projects from 226 proposals. On September 2, 2026, DARPA pre-released a $2.1 million SBIR topic for networked screwworm detection. Four funding streams, four eligibility regimes, four clockspeeds — and most applicants only know about one.
Read article